RAFAEL HOLDINGS INC (NYSE: RFL)

RAFAEL HOLDINGS INC (라파엘 홀딩스) is a clinical-stage biotechnology company listed on the New York Stock Exchange under the ticker RFL. As of June 11, 2025, shares closed at $2.0950, down 26.49% on a volume of 424,624.

---

Corporate Structure

• Executive Leadership

  • Howard Jonas, Executive Chairman
  • Bill Conkling, President & CEO
  • N. Scott Fine, CEO of Cyclo Therapeutics (wholly-owned subsidiary)

• Subsidiary Portfolio

  • Cyclo Therapeutics, LLC – Trappsol® Cyclo™ in Phase 3 trials for Niemann-Pick Disease Type C1 (NPC1)
  • LipoMedix Pharmaceuticals Ltd. – clinical-stage oncology therapeutics
  • Barer Institute Inc. – preclinical cancer metabolism research
  • Cornerstone Pharmaceuticals, Inc. – cancer metabolism-based therapeutics
  • Rafael Medical Devices, LLC – orthopedic surgical instruments
  • Day Three Labs, Inc. – cannabis product innovation

• Headquarters: Newark, New Jersey

• Exchange: NYSE

• Ticker: RFL

---

Recent Developments and News

• March 26, 2025 – Completed merger with Cyclo Therapeutics, Inc.

  • Rafael issued Class B common stock to Cyclo shareholders, representing approximately 22% of the combined company, based on the exchange ratio of 0.3525.
  • The 48-week interim analysis of TransportNPC™ is anticipated in mid-2025.

• May 5, 2025 – Announced revised subscription rights for a $25 million rights offering.

  • Holders as of May 9, 2025, will receive one non-transferable right per share; each right entitles the purchase of 0.603 of a share at $1.28.

• June 9, 2025 – Filed Amendment No. 5 to Schedule 13D/A.

  • Howard Jonas and affiliates acquired 16,400,770 shares at $1.28 per share; beneficially owns 14,688,994 Class B shares, representing 28.4%.

• June 11, 2025 – Filed Form 10-Q for the quarter ended March 31, 2025.

  • Reported a net loss and ongoing investments in research and development.

---

Financial and Strategic Analysis

Metric	Value
Share price (2025-06-11)	$2.0950
Daily change	–26.49%
Volume (2025-06-11)	424,624
Market cap (intraday)	$78.0 M
52-week range	$1.2722 – $3.1900
Price/Sales (TTM)	77.53
Price/Book (mrq)	1.18
Revenue (TTM)	$0.7 M
Net income (TTM)	–$50.5 M
Diluted EPS (TTM)	–$2.65
Total cash (mrq)	$48.3 M
Total debt/equity (mrq)	3.29%
Levered free cash flow (TTM)	–$54.3 M
Beta (5Y monthly)	0.92

• Liquidity and Capital Raising

  • Cash balance of $48.3 million supports ongoing clinical trials; the rights offering aims to raise $25 million, with support from Executive Chairman for any unsubscribed shares.

• Profitability

  • Reported net loss and negative EPS reflect the company's clinical-stage status, with no product sale revenues.

• Valuation Multiples

  • High price-to-sales ratio typical for pre-commercial biotech companies; price-to-book ratio near 1.2.

---

Market Position and Industry Context

• Clinical-Stage Biotech Sector

  • Focus on orphan diseases and oncology, with regulatory milestones impacting share performance.
  • Trials for TransportNPC™ related to Niemann-Pick Disease Type C1 and a Phase 2b study for Alzheimer's disease are part of the company's development pipeline.

• Competitive Landscape

  • Competitors include small-cap biotechs with late-stage assets; clinical trial outcomes significantly influence valuations.

• Investor Considerations

  • Integration following the merger with Cyclo Therapeutics; interim data release in mid-2025 will be critical for assessing future performance.
  • Corporate governance dynamics are influenced by Howard Jonas's substantial shareholding (28.4% of Class B).

---

tl;dr

• March 26, 2025: Rafael Holdings completed its merger with Cyclo Therapeutics, issuing new Class B shares and warrants.
• May 5 – May 29, 2025: Launched a $25 million rights offering at $1.28 per share; commitment from Executive Chairman to support any unsubscribed shares.
• June 9, 2025: Amendment to Schedule 13D/A indicates Howard Jonas holds 28.4% of Class B stock following the purchase of 16.4 million shares.
• Mid-2025: Interim analysis of the 48-week TransportNPC™ trial expected for Niemann-Pick Disease Type C1; results will be a significant factor for the company's valuation.